Erratum

Errata

This article corrects:

  1. Class II-specific histone deacetylase inhibitors MC1568 and MC1575 suppress IL-8 expression in human melanoma cells Volume 26, Issue 2, 193–204, Article first published online: 7 January 2013

In the paper by Venza et al. (2013), Figure 2C was missing. The Figure is printed correctly below.

Figure 2.

Effects of PMA on IL-8 promoter constructs. (A) The IL-8 promoter mutants used are shown: black, dark gray, light gray, and white boxes, wild-type sites; striped boxes, mutated sites. (B) GR-M cutaneous melanoma cells were transfected with the empty pGL-2 vector, wt IL-8 promoter, IL-8-97, IL-8-97/mC/EBPb, IL-8-97/mNF-kB, IL-8/AP-1, and IL-8/DCHOP/m(C/EBPb-NF-kB) promoters and subsequently treated with PMA for 18 h. The graph shows the luciferase activity in cells treated with PMA (black boxes) in comparison with untreated cells (gray boxes). Data are expressed as means ± SD of results in four independent experiments. β-galactosidase levels were determined for transfection efficiency. Significant *P < 0.001 PMA-treated versus untreated cells. (C) OCM-3 uveal melanoma cells were transfected with the empty pGL-2 vector, wt IL-8 promoter, IL-8-97, IL-8-97/mC/EBPb, IL-8-97/mNF-kB, IL-8/AP-1, and IL-8/DCHOP/m(C/EBPb-NF-kB) promoters and subsequently treated with PMA for 18 h. The graph shows the luciferase activity in cells treated with PMA (black boxes) in comparison with untreated cells (gray boxes). Data are expressed as means ± SD of results in four independent experiments. β-galactosidase levels were determined for transfection efficiency. Significant *P < 0.001 PMA-treate versus untreated cells.

Ancillary